Professional Documents
Culture Documents
Lance Armstrong is a unique phenomenon. He’s a talented athlete, a cancer survivor and a political activist.
He is in a league by himself. Or is he? As many people know, survivors of cancer are much more common
today. A recent National Center for Health Statistics report released by the American Cancer Society showed
a drop in cancer deaths for the second year in a row. Cancer patients as political and even business activists
are also increasingly common. In a Dec. 2006 column on MidwestBusiness.com, I wrote about this growing
phenomenon:
Various disease-oriented non-profit groups, charities and government groups are actively providing
venture financing to new biotech start-ups.
If the trend of socially driven popularization of biotech investment continues, investors would be looking
not just at financial returns but also at social returns.
Ultimately, this is what most patients want. Though it is not yet clear whether or not this will require new
legal frameworks, it is clear that it would involve new paradigms.
For example, it may imply regulations that make it easier for smaller companies to access the public or
semi-public financial markets. Let’s first discuss more about the increasing numbers of cancer survivors, the
reasons for that and the implications for future technologies.
Major Technology Trends
There are four major technology trends that have impacted cancer care over the past decade. I’ll discuss
each with some implications for the industry.
1. Earlier detection and diagnosis
2. Targeted therapies
3. Personalized medicine
4. Minimally invasive surgery
Earlier Detection, Diagnosis
The explosive advances in imaging technologies (computerized tomography (CT), magnetic resonance
imaging (MRI), ultrasound (U/S), mammography and others) have completely revolutionized cancer care.
With most cancers, earlier detection and diagnosis means more localized disease.
There are two implications to earlier and more localized disease: the disease has a higher chance of being
cured and surgical options generally figure more largely in the treatment of early disease. The second point
also relates in that advances in minimally invasive techniques have further contributed to growth in the
surgical management of cancer.
There have been several industry implications of earlier detection including an increase in demand for
radiology services. This has not only spurred growth in the sales of these complex machines but also in
1 of 3 11/17/2008 12:49 AM
Thinking about Life Sciences: Lance Armstrong and the Future of Cancer ... http://blog.aesisgroup.com//2007/01/22/lance-armstrong-and-the-future-of...
2 of 3 11/17/2008 12:49 AM
Thinking about Life Sciences: Lance Armstrong and the Future of Cancer ... http://blog.aesisgroup.com//2007/01/22/lance-armstrong-and-the-future-of...
interventions for previously unresectable metastases are all part of the surgical armamentarium.
The implications - which will continue in the future - will be a further stimulus to interventional radiology,
ambulatory surgery centers and the surgical device market serving this sector. We’ve seen a remarkable
confluence of technology trends that have (among other factors) contributed to recent successes in the
“war against cancer”.
As implied earlier and in other columns, we may also be amid an inflection point in business models for
biotech and medical technology in which patients and patient-care groups become increasingly involved in the
expensive financing of such technologies.
While unique in his own way, Armstrong’s efforts are one of many in this direction. What is unique about
Armstrong is that he is applying his exquisite sense of timing in “entering the cancer field”. On the bicycle:
… Armstrong was the king of the decisive moment. He knew exactly when to put the hammer down, and when
he did, you could see in the faces of his rivals that they knew they were competing for second place. Source: Freelance
writer Nick Swallow
Let’s see if the face of cancer is beginning to give that look as if it is doomed to place second.
Cancer Personalized medicine cancer diagnostics minimally invasive surgery personalised medicine Aesis Research Group Ogan Gurel MD
3 of 3 11/17/2008 12:49 AM